Compare Stocks: ATNM, DTSQ, BDTX, and RANI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$0.81 -0.2%	$0.98	$0.81 ▼ $1.81	$25.41M	-0.02	141,570 shs	92,086 shs
BDTX Black Diamond Therapeutics	$1.78 +2.6%	$1.86	$1.60 ▼ $4.94	$99.42M	3.28	831,044 shs	916,161 shs
DTSQ DT Cloud Star Acquisition	$11.33 +0.1%	$11.31	$10.38 ▼ $12.90	$100.76M	-0.01	3,870 shs	329 shs
RANI Rani Therapeutics	$0.82 +2.3%	$0.79	$0.44 ▼ $3.87	$99.27M	0.78	1.08 million shs	1.12 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	-0.18%	-6.52%	-17.43%	-34.68%	-51.20%
BDTX Black Diamond Therapeutics	+2.59%	+1.14%	-11.44%	-36.88%	-37.10%
DTSQ DT Cloud Star Acquisition	-0.04%	0.00%	+0.27%	+1.21%	+9.36%
RANI Rani Therapeutics	+2.33%	+0.09%	+6.31%	-14.59%	+49.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$0.81 -0.2%	$0.98	$0.81 ▼ $1.81	$25.41M	-0.02	141,570 shs	92,086 shs
BDTX Black Diamond Therapeutics	$1.78 +2.6%	$1.86	$1.60 ▼ $4.94	$99.42M	3.28	831,044 shs	916,161 shs
DTSQ DT Cloud Star Acquisition	$11.33 +0.1%	$11.31	$10.38 ▼ $12.90	$100.76M	-0.01	3,870 shs	329 shs
RANI Rani Therapeutics	$0.82 +2.3%	$0.79	$0.44 ▼ $3.87	$99.27M	0.78	1.08 million shs	1.12 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	-0.18%	-6.52%	-17.43%	-34.68%	-51.20%
BDTX Black Diamond Therapeutics	+2.59%	+1.14%	-11.44%	-36.88%	-37.10%
DTSQ DT Cloud Star Acquisition	-0.04%	0.00%	+0.27%	+1.21%	+9.36%
RANI Rani Therapeutics	+2.33%	+0.09%	+6.31%	-14.59%	+49.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	3.00	Buy	$5.00	517.28% Upside
BDTX Black Diamond Therapeutics	2.73	Moderate Buy	$9.83	452.43% Upside
DTSQ DT Cloud Star Acquisition	2.00	Hold	N/A	N/A
RANI Rani Therapeutics	2.60	Moderate Buy	$8.75	967.07% Upside

Current Analyst Ratings Breakdown

Latest ATNM, DTSQ, BDTX, and RANI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	RANI Rani Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	BDTX Black Diamond Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
7/13/2026	DTSQ DT Cloud Star Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
6/29/2026	DTSQ DT Cloud Star Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
6/24/2026	RANI Rani Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/22/2026	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/22/2026	BDTX Black Diamond Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/22/2026	BDTX Black Diamond Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/20/2026	RANI Rani Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
5/18/2026	BDTX Black Diamond Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	$90K	282.38	N/A	N/A	$1.31 per share	0.62
BDTX Black Diamond Therapeutics	$70M	1.46	$0.54 per share	3.29	$1.97 per share	0.90
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	$1.63M	62.32	N/A	N/A	$0.34 per share	2.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	-$0.75	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
BDTX Black Diamond Therapeutics	$22.37M	-$0.77	N/A	N/A	N/A	N/A	-30.18%	-23.91%	8/6/2026 (Estimated)
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	-$29.67M	-$0.41	N/A	N/A	N/A	N/A	-206.46%	-83.95%	8/6/2026 (Estimated)

Latest ATNM, DTSQ, BDTX, and RANI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BDTX Black Diamond Therapeutics	-$0.18	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	RANI Rani Therapeutics	-$0.05	N/A	N/A	N/A	$0.93 million	N/A
8/3/2026	Q2 2026	DTSQ DT Cloud Star Acquisition	N/A	$0.0630	N/A	$0.0630	N/A	N/A
5/15/2026	Q1 2026	RANI Rani Therapeutics	-$0.06	-$0.04	+$0.02	-$0.04	$1.13 million	$1.71 million
5/8/2026	Q1 2026	DTSQ DT Cloud Star Acquisition	N/A	$0.0220	N/A	$0.0220	N/A	N/A
5/7/2026	Q1 2026	BDTX Black Diamond Therapeutics	-$0.18	-$0.16	+$0.02	-$0.16	$25.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
BDTX Black Diamond Therapeutics	N/A	8.46	8.46
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	3.40	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
BDTX Black Diamond Therapeutics	95.47%
DTSQ DT Cloud Star Acquisition	N/A
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	0.60%
BDTX Black Diamond Therapeutics	9.29%
DTSQ DT Cloud Star Acquisition	52.88%
RANI Rani Therapeutics	26.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	30	31.38 million	29.32 million	Optionable
BDTX Black Diamond Therapeutics	90	57.30 million	51.98 million	Optionable
DTSQ DT Cloud Star Acquisition	N/A	8.90 million	4.19 million	N/A
RANI Rani Therapeutics	110	123.88 million	90.77 million	Optionable

ATNM, DTSQ, BDTX, and RANI Headlines

Recent News About These Companies

Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair

August 4 at 8:31 AM | quiverquant.comQ

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Moderate Buy" from Analysts

August 4 at 4:13 AM | marketbeat.com

Rani Therapeutics (RANI) Projected to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Rani Therapeutics (NASDAQ:RANI) CEO Talat Imran Sells 8,014 Shares of Stock

July 29, 2026 | insidertrades.com

Insider Selling: Rani Therapeutics (NASDAQ:RANI) CEO Sells 8,014 Shares

July 28, 2026 | marketbeat.com

Insider Buying: Rani Therapeutics (NASDAQ:RANI) Director Buys $24,840.00 in Stock

July 28, 2026 | marketbeat.com

Rani Therapeutics (NASDAQ:RANI) CEO Buys 35,000 Shares

July 28, 2026 | marketbeat.com

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 20, 2026 | globenewswire.com

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

July 15, 2026 | globenewswire.com

Rani Therapeutics Holdings (RANI) Declines 7.95%, Testing Key Support at $0.60 - Strangle Setup

July 14, 2026 | donanimhaber.comD

Rani Therapeutics Holdings Inc - Ordinary Shares Class A

July 13, 2026 | money.usnews.com

Rani Therapeutics enters R&D collaboration with PegBio to expand obesity pipeline across multiple novel candidates

July 13, 2026 | pharmabiz.comP

Why Did Rani Therapeutics (NASDAQ:RANI) Announce New Collaboration?

July 10, 2026 | kalkinemedia.comK

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Consensus Rating of "Moderate Buy" by Brokerages

July 10, 2026 | marketbeat.com

China's PegBio Pops on Deal to Develop Oral Formulations for Obesity, Metabolic Drugs With US' Rani Therapeutics

July 10, 2026 | yicaiglobal.comY

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

July 9, 2026 | globenewswire.com

Rani Therapeutics (NASDAQ:RANI) Stock Price Down 2.3% - Should You Sell?

July 9, 2026 | marketbeat.com

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

June 29, 2026 | globenewswire.com

Rani Therapeutics Shareholders Back Board and Auditor at Meeting

May 29, 2026 | tipranks.com

Rani Therapeutics Announces $20 Million Equity Financing

May 27, 2026 | tipranks.com

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

May 26, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, DTSQ, BDTX, and RANI Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$0.81 0.00 (-0.18%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$0.82 +0.01 (+0.99%)

As of 04:00 AM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Black Diamond Therapeutics NASDAQ:BDTX

$1.78 +0.05 (+2.59%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$1.80 +0.02 (+1.12%)

As of 08:00 AM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

DT Cloud Star Acquisition NASDAQ:DTSQ

$11.33 +0.01 (+0.09%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$11.30 -0.03 (-0.26%)

As of 08/4/2026 07:34 PM Eastern

DT Cloud Star Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2022 and is based in Brooklyn, New York.

Rani Therapeutics NASDAQ:RANI

$0.82 +0.02 (+2.33%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$0.83 +0.01 (+1.46%)

As of 08:12 AM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, DTSQ, BDTX, and RANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, DTSQ, BDTX, and RANI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, DTSQ, BDTX, and RANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, DTSQ, BDTX, and RANI Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

Black Diamond Therapeutics NASDAQ:BDTX

DT Cloud Star Acquisition NASDAQ:DTSQ

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, DTSQ, BDTX, and RANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, DTSQ, BDTX, and RANI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, DTSQ, BDTX, and RANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, DTSQ, BDTX, and RANI Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

Black Diamond Therapeutics NASDAQ:BDTX

DT Cloud Star Acquisition NASDAQ:DTSQ

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools